Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 15233859Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2025 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2025
Linked Award Amount
$4.6M
Full award amounts, FY2025
Award Records
9
Records listing this PI
Award-Linked Rank
#1,658
By linked amount among FY2025 PIs
Earliest Year Loaded
2025
ScienceDex PI coverage
Award data coverage
ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.
Single fiscal year on record (FY2025): $4.6M in linked award amounts across 9 award records · Award-linked rank #1658.
FY2025 award records by amount
NIH award records listing Swee Lay Thein as a PI. Multi-PI records show the full award amount for context.
- 1ZIAHL006233-09ZIAStudies of the Natural History of Sickle Cell Disease$958.1Kaward amount
- 1ZIAHL006241-07ZIAHuman Specimen Collection to Support Basic and Clinical Research$775.6Kaward amount
- 1ZIAHL006296-03ZIAObservational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease$684.3Kaward amount
- 1ZIAHL006240-07ZIAGenotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$684.3Kaward amount
- 1ZIAHL006284-03ZIAA Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell disease$684.3Kaward amount
- 1ZIAHL006266-05ZIAEvaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$456.2Kaward amount
- 1ZIAHL006282-02ZIAA Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease$228.1Kaward amount
- 1ZIAHL006283-03ZIAExploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCD$45.6Kaward amount
- 1ZIAHL006239-07ZIAA Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$45.6Kaward amount
Award organization
Organizations that administered FY2025 awards listing Swee Lay Thein as a PI.
FY2025 award administered by National Heart, Lung, and Blood Institute ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2025First NIH AwardNational Heart, Lung, and Blood Institute
- 2025$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #1658
- 2025Entered Top 25% NationallyRanked #1658
- 2025Entered Top 10% NationallyRanked #1658